Biotech investing requires an iron will due to risks in the drug discovery process; it holds potential for high returns but demands a long-term view.
CRISPR Therapeutics is the industry leader in gene editing with its CRISPR/Cas9 therapy Casgevy, showing promising potential in treating sickle cell disease.
[
Collection
]
[
|
...
]